Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 4, 2007, Pages 297-304

  Kato, Shigeaki ^a,b   Kim, Mi Sun ^a,b   Yamaoka, Kazuyoshi ^a,b   Fujiki, Ryoji ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Coregulator; Corepressor; Transcriptional repression; Vitamin D; Vitamin D receptor

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; VITAMIN D; VITAMIN D RECEPTOR;

BINDING AFFINITY; CHROMATIN STRUCTURE; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; LIGAND BINDING; NUCLEAR REACTOR; PRIORITY JOURNAL; PROTEIN MOTIF; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION TERMINATION; VITAMIN D METABOLISM;

ANIMALS; ERGOCALCIFEROLS; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, CALCITRIOL; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; VITAMIN D RESPONSE ELEMENT;

EID: 34250649804     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3281c55f16     Document Type: Review

References (60)

1. Salle BL, Delvin EE, Lapillonne A, et al. Perinatal metabolism of vitamin D. Am J Clin Nutr 2000; 71:1317S-1324S.
2. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80:1689S-1696S.
3. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997; 16:391-396.
4. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13:325-349.
5. Rachez C, Freedman LP. Mediator complexes and transcription. Curr Opin Cell Biol 2001; 13:274-280.
6. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147:5542-5548.
7. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83:835-839.
8. Whitfield GK, Jurutka PW, Haussler CA, et al. Nuclear vitamin D receptor: structure-function, molecular control of gene transcription, and novel bioactions. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D, 2nd ed. Oxford: Elsevier Academic Press; 2005. pp. 219-261.
9. Renaud JP, Rochel N, Ruff M, et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378:681-689.
10. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95:927-937.
11. Rochel N, Wurtz JM, Mitschler A, et al. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000; 5:173-179.
12. Kato S. The function of vitamin D receptor in vitamin D action. J Biochem (Tokyo) 2000; 127:717-722.
13. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006; 20:1405-1428.
14. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
15. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 2001; 11:497-504.
16. Dong X, Lutz W, Schroeder TM, et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A 2005; 102:16007-16012.
17. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6:838-849.
18. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128:707-719. This is a state-of-the-art and comprehensive review to understand chromatin remodeling and histone modification for transcriptional controls. Basic knowledge for transcriptional controls by transcription factors including nuclear receptors is concisely described and illustrated.
19. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14:121-141.
20. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108:465-474.
21. Li X, Lonard DM, Jung SY, et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 2006; 124:381-392.
22. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437:436-439.
23. Garcia-Bassets I, Kwon YS, Telese F, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007; 128:505-518.
24. Belandia B, Parker MG. Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 2003; 114:277-280.
25. Emerson BM. Specificity of gene regulation. Cell 2002; 109:267-270.
26. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108:475-487.
27. Kitagawa H, Fujiki R, Yoshimura K, et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003; 113:905-917.
28. Lu X, Meng X, Morris CA, Keating MT. A novel human gene, WSTF, is deleted in Williams syndrome. Genomics 1998; 54:241-249.
29. Kim S, Shevde NK, Pike JW. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res 2005; 20:305-317.
30. Dusso AS. Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 2003; 85:S6-S9.
31. Akerstrom G, Hellman P, Hessman O, et al. Parathyroid glands in calcium regulation and human disease. Ann N Y Acad Sci 2005; 1040:53-58.
32. Takeyama K, Kitanaka S, Sato T, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997; 277:1827-1830.
33. Murayama A, Takeyama K, Kitanaka S, et al. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun 1998; 249:11-16.
34. Murayama A, Takeyama K, Kitanaka S, et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 1999; 140:2224-2231.
35. Murayama A, Kim MS, Yanagisawa J, et al. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J 2004; 23:1598-1608.
36. Kato S, Yanagisawa J, Murayama A, et al. The importance of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene in vitamin D-dependent rickets. Curr Opin Nephrol Hypertens 1998; 7:377-383.
37. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1992; 89:8097-8101.
38. Mackey SL, Heymont JL, Kronenberg HM, Demay MB. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid X receptor. Mol Endocrinol 1996; 10:298-305.
39. Russell J, Ashok S, Koszewski NJ. Vitamin D receptor interactions with the rat parathyroid hormone gene: synergistic effects between two negative vitamin D response elements. J Bone Miner Res 1999; 14:1828-1837.
40. Okazaki T, Nishimori S, Ogata E, Fujita T. Vitamin D-dependent recruitment of DNA-PK to the chromatinized negative vitamin D response element in the PTHrP gene is required for gene repression by vitamin D. Biochem Biophys Res Commun 2003; 304:632-637.
41. Nishishita T, Okazaki T, Ishikawa T, et al. A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J Biol Chem 1998; 273:10901-10907.
42. Kim MS, Fujiki R, Murayama A, et al. 1Alpha,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol 2007; 21:334-342. This paper reports the E-box-type nVDREs in the PTH and PTHrP gene promoters.
43. Zhang W, Tsuchiya T, Yasukochi Y. Transitional change in interaction between HIF-1 and HNF-4 in response to hypoxia. J Hum Genet 1999; 44:293-299.
44. McNamara P, Seo SP, Rudic RD, et al. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell 2001; 105:877-889.
45. Fujiki R, Kim MS, Sasaki Y, et al. Ligand-induced transrepression by VDR through association of WSTF with acetylated histones. EMBO J 2005; 24:3881-3894.
46. Treuter E, Gustafsson JA. Wrestling rules in transrepression: as easy as SUMO-1, -2, -3? Mol Cell 2007; 25:178-180.
47. Ohtake F, Baba A, Takada I, et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007; 446:562-566.
48. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990; 62:1189-1204.
49. Schule R, Rangarajan P, Kliewer S, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990; 62:1217-1226.
50. Suzawa M, Takada I, Yanagisawa J, et al. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 2003; 5:224-230.
51. Bastie JN, Balitrand N, Guidez F, et al. 1 alpha,25- dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol Endocrinol 2004; 18:2685-2699.
52. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122:707-721.
53. Waterman WR, Xu LL, Tetradis S, et al. Glucocorticoid inhibits the human pro-interleukin lbeta gene (ILIB) by decreasing DNA binding of transactivators to the signal-responsive enhancer. Mol Immunol 2006; 43:773-782.
54. Lazar MA. Nuclear receptor corepressors. Nucl Recept Signal 2003; 1:e001.
55. Fernandes I, Bastien Y, Wai T, et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 2003; 11:139-150.
56. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20:2871-2886.
57. Winkler GS, Mulder KW, Bardwell VJ, et al. Human Ccr4-Not complex is a ligand-dependent repressor of nuclear receptor-mediated transcription. EMBO J 2006; 25:3089-3099.
58. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437:759-763. This study is a very interesting and important report in terms of receptor protein modifications and corepressor recruitment. Ligand binding to peroxisome proliferator-activated receptor γ causes a structural change. This results in the exposure of a previously hidden region in the ligand binding domain. When this region is SUMOylated, protein modification by SUMO modifies the receptor's ability to stably associate with corepressors. This is the first description of the physiological significance of SUMOylation of receptors - a modification proven to be associated with ligand-induced transcriptional repression.
59. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007; 25:57-70.
60. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26:898-915.